NCT05348148 Comparison of the Effects for Lightening the Shiners Among Different Treatments for Rhinitis
| NCT ID | NCT05348148 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Camillians Saint Mary's Hospital Luodong |
| Condition | Allergic Rhinitis |
| Study Type | INTERVENTIONAL |
| Enrollment | 450 participants |
| Start Date | 2020-06-16 |
| Primary Completion | 2032-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 450 participants in total. It began in 2020-06-16 with a primary completion date of 2032-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Background: Shiners are caused when blood and other fluids accumulate in the infraorbital groove. It develops resulting from lots of problems. In patient with rhinitis, either allergic rhinitis or non-allergic rhinitis, shiners are believed to be caused by venous stasis resulting from nasal congestion. This study is aiming that comparison of the effectiveness of treatment of rhinitis (either allergic rhinitis or non-allergic rhinitis) to lighten not only the rhinitis but also the shiners. Randomized control studies. Design: The investigators will recruit children (6-12 y/0), adolescent (13-18 y/o), or adults (19-65 y/o) with either allergic rhinitis or non-allergic rhinitis, and patients will be randomly assigned to groups (oral antihistamine, combined nasal corticosteroids with oral antihistamine, combined nasal corticosteroids with oral antihistamine plus nasal decongestant, combined nasal corticosteroids with oral antihistamine plus nasal irrigation, combined oral antihistamine with nasal irrigation, or nasal antihistamine only). Digital image will be recorded and analyzed to compare the change of shiners between before and after treatment for rhinitis. The clinical data were collected including patient's data, history, laboratory data, Pediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ), Adolescent Rhinoconjunctivitis Quality of Life Questionnaire (AdolRQLQ), or mini Rhinoconjunctivitis Quality of Life Questionnaire (mini-RQLQ), and medications. The primary outcome is to answer whether the levels of shiners can be alleviated by using therapies in patient with rhinitis. And the secondary outcome is to figure out which therapies work most effectively. Keywords: allergic rhinitis, vasomotor rhinitis, shiners, nasal corticosteroids
Eligibility Criteria
Inclusion Criteria: * Clinical diagnosis of moderate to severe rhinitis, either allergic rhinitis or non-allergic rhinitis. Exclusion Criteria: * Chronic rhinosinusitis * Trauma to the forehead or nose * Face surgery * Malignancy * Pregnancy * Respiratory tract infections within a week before beginning the study * Usage of medications for rhinitis within a week before beginning the study
Contact & Investigator
Cheng-Tsung Yang
PRINCIPAL INVESTIGATOR
Camillian Saint Mary's Hospital Luodong
Frequently Asked Questions
Who can join the NCT05348148 clinical trial?
This trial is open to participants of all sexes, aged 6 Years or older, up to 65 Years, studying Allergic Rhinitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05348148 currently recruiting?
Yes, NCT05348148 is actively recruiting participants. Contact the research team at jjbulebeer@gmail.com for enrollment information.
Where is the NCT05348148 trial being conducted?
This trial is being conducted at Luodong, Taiwan.
Who is sponsoring the NCT05348148 clinical trial?
NCT05348148 is sponsored by Camillians Saint Mary's Hospital Luodong. The principal investigator is Cheng-Tsung Yang at Camillian Saint Mary's Hospital Luodong. The trial plans to enroll 450 participants.